Beijing Centergate Technologies(000931.SZ) subsidiary Duoduo Pharmaceutical's marketing authorization application for Calcium Dobesilate Capsules has been accepted.

Beijing Centergate Technologies (000931.SZ) announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. (hereinafter referred to as "Duoduo Pharmaceutical") recently received a Notice of Acceptance issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and the marketing authorization application for Calcium Dobesilate Capsules (specification: 0.5g) has been accepted. The indications for Calcium Dobesilate Capsules are: 1. Treatment of microangiopathy: diabetic microangiopathy retinopathy and glomerulosclerosis (Kimmelstiel-Wilson syndrome); microvascular damage accompanied by increased capillary fragility and permeability, capillaropathy, and acrocyanosis. 2. Adjuvant treatment of chronic venous insufficiency (varicose vein syndrome) and its sequelae (post-thrombotic syndrome, leg ulcers, purpuric dermatitis and other stasis dermatoses, peripheral vascular stasis edema, etc.).